CORE
🇺🇦
make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Using Mendelian randomisation to identify opportunities for type 2 diabetes prevention by repurposing medications used for lipid management
Authors
Shoa Clarke
Todd L Edwards
+10 more
Kent Heberer
Jacob M Keaton
Nikhil K Khankari
Kyung M Lee
Julie Lynch
Donald Miller
Peter Reaven
Megan Shuey
Marijana Vujkovic
Venexia M Walker
Publication date
1 January 2022
Publisher
'Elsevier BV'
Doi
Cite
View
on
PubMed
Abstract
Background: Maintaining a healthy lifestyle to reduce type 2 diabetes (T2D) risk is challenging and additional strategies for T2D prevention are needed. We evaluated several lipid control medications as potential therapeutic options for T2D prevention using tissue-specific predicted gene expression summary statistics in a two-sample Mendelian randomisation (MR) design. Methods: Large-scale European genome-wide summary statistics for lipids and T2D were leveraged in our multi-stage analysis to estimate changes in either lipid levels or T2D risk driven by tissue-specific predicted gene expression. We incorporated tissue-specific predicted gene expression summary statistics to proxy therapeutic effects of three lipid control medications [i.e., statins, icosapent ethyl (IPE), and proprotein convertase subtilisin/kexin type-9 inhibitors (PCSK-9i)] on T2D susceptibility using two-sample Mendelian randomisation (MR). Findings: IPE, as proxied via increased FADS1 expression, was predicted to lower triglycerides and was associated with a 53% reduced risk of T2D. Statins and PCSK-9i, as proxied by reduced HMGCR and PCSK9 expression, respectively, were predicted to lower LDL-C levels but were not associated with T2D susceptibility. Interpretation: Triglyceride lowering via IPE may reduce the risk of developing T2D in populations of European ancestry. However, experimental validation using animal models is needed to substantiate our results and to motivate randomized control trials (RCTs) for IPE as putative treatment for T2D prevention. Funding: Only summary statistics were used in this analysis. Funding information is detailed under Acknowledgments. © 2022Open access journalThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at
[email protected]
Similar works
Full text
Open in the Core reader
Download PDF
Available Versions
Sustaining member
The University of Arizona
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:repository.arizona.edu:101...
Last time updated on 10/10/2022
PubMed Central
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:pubmedcentral.nih.gov:9062...
Last time updated on 12/07/2022
Supporting member
Explore Bristol Research
See this paper in CORE
Go to the repository landing page
Download from data provider
oai:research-information.bris....
Last time updated on 25/04/2022